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Head and neck cancer is the sixth leading type of cancer with 90 percent of head 
and neck cancer arising from squamous cell lining on the epithelium of the oral and nasal 
cavity, pharynx, and salivary gland. Even with tremendous achievements on 
chemotherapeutic drugs and therapies, the long-term prognosis of patients with advanced 
head and neck squamous cell carcinoma (HNSCC) has shown little improvement over the 
last three decades. Cisplatin is one of widely used chemotherapeutic drugs for multiple
	  
	  
cancers, including head and neck cancer, but the prolonged use of this drug is limited by 
its toxicity and by the development of resistance. To overcome these major roadblocks to 
improved prognosis requires mechanism-based therapeutic strategies to maximize the 
antitumor effect of drugs while limiting their toxicities. Cisplatin exerts anticancer effects 
via multiple mechanisms, yet its most prominent mode of action involves the generation 
of DNA lesions followed by the activation of the DNA damage response and the 
induction of BCL-2 family-dependent mitochondrial apoptosis. DNA damage activates a 
tumor suppressor p53 to induce apoptosis. One of its functions is to induce the expression 
of several pro-apoptotic proteins such as Noxa, which binds to an anti-apoptotic BCL-2 
family protein, MCL-1 (myeloid leukemia cell-1) to inactivate its pro-survival function 
and induce apoptosis. We examined Noxa expression and apoptosis induced by cisplatin 
in p53-wild-type HN30 and HN31, p53-truncated and inactive HN4 and HN12, and p53-
deleted HN22 and HN8 HNSCC cell lines. We found that Noxa was induced in HN30 
and HN31 cells and down-regulation of Noxa by shRNA (short-hairpin RNA) decreased 
apoptosis, indicating Noxa contribution to cisplatin-induced apoptosis. Interestingly, 
cisplatin treatment induced Noxa and apoptosis even in p53-deleted HN22 and HN8 
cells, suggesting the existence of the p53-independent pathways for the induction of 
Noxa. Based on these observations, we hypothesized that modulation of Noxa/MCL-1 
axis could mimic cisplatin-induced cell death. We found that Noxa overexpression 
induced cell death in all cell lines tested regardless of p53 status. This finding could be 
applicable as a potential therapeutic strategy to treat head and neck cancer.
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INTRODUCTION 
 
1.1 Cancer 
Cancer is a genetic disease caused by altering genes in our body that control the 
growth and dividing functions. This leading cause of death worldwide is estimated to kill 
about 589,430 Americans in 2015 and about 1.65 million new cases are expected in 2015 
(www.cancer.gov). According to WHO, new cases of cancer will increase from 14 
million in 2012 to 22 million within the next two decades. Among the various cancer 
types, the most common causes of death are lung, liver, stomach, colorectal, breast, and 
esophageal cancer (www.who.org). With increasing number of deaths and new cases, it is 
important for us to comprehend the molecular mechanisms of tumorigenesis and cell 
death to specifically enhance it in cancer cells.  
There are many known factors that increase the risk of cancer. Cigarette smoking 
is highly related to increase the risk for many types of cancer such as bladder, kidney, 
esophageal, lung, oral cavity, and stomach cancers. It is believed that cigarette smoking 
causes about 30% of all cancer deaths in United States (www.cancer.gov). Infections by 
viruses and bacteria can also increase the risk of cancer. For example, human 
papillomavirus (HPV), Hepatitis B and C viruses, and helicobacter pylori can increase the 
risk for cancers. Radiation is another factor to increase in cancer development. Ultraviolet 
radiation from sunlight, x-rays, CT scans, and fluoroscopy are some of the examples for 
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radiation. Factors like diet, alcohol consumption, physical activity, obesity, and 
environmental risk factors may affect the risk of cancer. 
 
1.2 Head and Neck Cancer 
Head and neck cancer is a general term that branches out to a specific type and 
place of cancer, and 90 percent of head and neck cancers arise from squamous cell lining 
the epithelium of the oral and nasal cavity, pharynx, larynx, paranasal sinuses, and 
salivary glands [3]. Head and neck squamous cell carcinoma (HNSCC) is the sixth leading 
type of cancer with estimated 650,000 of new cancer cases and 350,000 of cancer deaths 
worldwide per year [2]. About 3 percent of all cancers in the United States are believed to 
be head and neck cancer [12], which occurs twice as common among men as it does 
among women [1]. It is known that 80% of cases eventually become metastatic to invade 
the regional lymph nodes of the neck [2] and five-year survival rate of patients with 
HNSCC is 40 to 50 percent.  
The two highest risk factors for head and neck cancer are alcohol and tobacco 
(chewing and smokeless) use. About 75 percent of head and neck cancer are caused by 
tobacco and alcohol use and people have higher risk when they use both compared to 
people who use one or the other [8-10]. These high risk factors affect oral cavity, 
oropharynx, hypopharynx, and larynx cancers [4-7]. Another high risk factor that is 
currently increasing the cause of oropharyngeal cancer in tonsils and base of tongue is 
with infection of human papillomavirus-16 (HPV-16) [11]. Currently in the United States, 
more than half of oropharyngeal cancer is linked to HPV-16 [16].  
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Treatment for head and neck cancer varies with where the cancer is located and 
the stage of the cancer. Majority of HNSCC treatment begins with radiation or 
chemotherapy, and followed by surgery, however, treatment options are plan accordingly 
to each patient. With head and neck cancer, there are five different stages starting from 
zero to four. At stage 0, the tumor just begins to grow and is not found in deeper tissues. 
A primary tumor with 2 cm or smaller in size with no cancer cells in nearby structures or 
lymph nodes is considered as stage I. Tumor size of 2 to 4 cm is stage II and tumor size 
greater then 4 cm is considered as stage III. Stage IV in head and neck cancer has three 
different types (A, B, and C). Stage IVA means that the tumor is in any size but is not 
found in lymph nodes or other parts of the body. Stage IVB represents that the tumor has 
migrated to lymph nodes and Stage IVC means that the tumor has spread to lymph nodes 
as well as other distant sites of the body (www.cancercenter.com). 
For early or localized disease (stage I-II), either surgery or radiation therapy is 
needed and patients with locally advanced disease (stage III-IV), both chemotherapy and 
radiation therapy are required to increase the cure rate. Many different types of 
chemotherapeutic drugs are used to cure head and neck cancers. The drugs such as 
cisplatin, paclitaxel, and carboplatin are widely used in conjunction to treat the tumor. 
 
1.3 Cisplatin 
Cisplatin is a chemotherapeutic drug known as “the penicillin of cancer”, because 
of its wide use of treating cancers including testicular, head and neck, bladder, 
esophageal, non-small cell lung, stomach, breast, cervical, and prostate. Michel Peyrone 
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created cisplatin in mid-19th century and it wasn’t used until 1960s for biological effects. 
Cisplatin was first researched with E. coli. and scientists have found that it inhibits 
reproduction and prevent binary fission [15]. It was then researched on rats and the Food 
and Drug Administration approved cisplatin in 1978 for multiple cancer treatments.  
Cisplatin (cis-PtCl2(NH3)2) consists of 11 atoms with platinum in the center 
(Figure 1). Even though cisplatin is widely used as a chemotherapeutic drug to cure 
cancer, we do not know the specific mechanisms on how cisplatin induces particular 
proteins to stimulate cancer cell death. The platinum in cisplatin is the key to induce cell 
death in cancer cells. Cisplatin works as a simple nucleophilic substitution reaction. 
When cisplatin is intravenously injected into the body, the chlorine atom gets replaced by 
a hydroxyl group and binds covalently to the DNA in the cell (Figure 2) [15]. Cisplatin 
crosslinks with DNA as monoadduct, interstrand crosslink, intrastrand crosslink or DNA-
protein crosslink which acts on adjacent N-7 guanine forming 1, 2 intrastrand crosslink [13, 
14]. Also, cisplatin can bind to a protein on one side and bind to DNA on the other side. 
This cisplatin-protein interaction plays a critical role to protect cisplatin from the DNA 
repair mechanisms in the cell [15]. Failure to repair the DNA causes replication arrest and 
cell death occurs. 
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Figure 1: Structural formula of cisplatin. The chemical name for cisplatin is Cis-
Platinum(II)diamine dichloride (cis-PtCl2(NH3)2) 
 
 
Figure 2: Cisplatin crosslinks with DNA and inhibit replication to induce apoptosis 
[modified26] 
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1.4 Cell Death 
 Apoptosis, autophagy, and necrosis are three major types of cell death. Apoptosis 
(from Greek apo, “by, from” and ptosis, “fall”)-stimulated cells shrink due to 
cytoskeleton collapses, nuclear envelop disassembly and fragmentation as well as 
cleavage of DNA. Over all, cell death through apoptosis is neat and clean as the bodies of 
blebs are well cleared out by phagocytic cells. Autophagy (from Greek auto-, “self” and 
phagein, “to eat”) is another type of cell death that is not as well studied as apoptosis. 
Interestingly, autophagy can increase cell survival when the cell suffers from starvation 
by breaking down its own cellular components to maintain cellular energy level. Thus, 
autophagy is considered as an adaptive response to stress that can promote survival or 
death [17]. Necrosis is stimulated by extreme stress towards the cell or tissue by infection, 
toxins, or trauma, and the cell swells and bursts as the integrity of the cell membrane 
decreases. Unlike apoptosis, necrosis is always very harmful and can be fatal. 
Apoptosis, also known as programmed cell death, manages proper homeostasis of 
highly controlled multicellular organism. If apoptosis does not occur properly, cells could 
develop into cancers and autoimmunity. On the other hand, immoderate cell death causes 
cardiovascular disease like stroke and heart attack and neurodegenerative disorders like 
Alzheimer, Parkinson, and Huntington disease. With the importance of homeostasis, 
regulation of apoptosis must be in absolute control in order for proper function of the 
multicellular organisms. 
Two main pathways of apoptosis are extrinsic (cytoplasmic) and intrinsic 
(mitochondrial) pathways (Figure 3). In the extrinsic pathway, ligands such as Fas-L or 
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TNF (tumor necrosis factor) bind to its corresponding death receptors FAS or TNFR1 
(tumor necrosis factor receptor 1), respectively, and the intracellular regions of the 
receptors engage specific adapter proteins to cleave pro-caspases to be activated. The 
activated initiator caspases (e.g. caspase-8 or -10) have ability to activate other pro-
caspases (e.g. caspase-3), resulting in amplifying proteolytic cascade. For example, Fas-
FasL complex recruits FADD (Fas-associated death domain) protein and pro-caspase-8 is 
cleaved to become an active caspase-8. Activated caspase-8 activates caspase-3, which 
triggers apoptosis [18]. When cells are disrupted by stress, damaged cytoskeleton and 
DNA can activate the intrinsic pathway to initiate apoptosis. This pathway engages the 
BCL-2 family proteins that regulate cell death through either induction or inhibition of 
pro- and anti-apoptotic proteins. Activation of pro-apoptotic proteins creates channels at 
the outer mitochondrial membrane, resulting in the release of cytochrome c from the 
mitochondrial intermembrane space to cytosol through MOMP (mitochondrial outer 
membrane permeabilization). Then cytochrome c binds to APAF1 (apoptotic protease 
activating factor 1) to be activated. Activated APAF1 binds to an initiator caspase, 
caspase-9 to form a complex called apoptosome, which activates an executor caspase, 
caspase-3 to initiate apoptosis [19].  
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Figure 3: Simplified diagram of the intrinsic and extrinsic pathways of apoptosis [Modified 
27]. 
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1.5 BCL-2 Family 
A group of proteins that regulate mitochondrial pathway of apoptosis is called the 
BCL-2 family of proteins. These proteins only share a number of specific sequences 
homology called BH (BCL-2 homology) domains. The family is subdivided in three 
classifications according to its function and by which BH domain it has. Currently, four 
groups of BH domains are identified (BH1, BH2, BH3, and BH4) and the first group is 
classified as pro-apoptotic multi-domain BCL-2 effectors. The proteins such as BAK and 
BAX contain multiple BH domains that stimulate apoptosis by triggering MOMP. BCL-2, 
BCL-XL, MCL-1, A1, and BCL-w are known as the second classification, which refers to 
the anti-apoptotic BCL-2 proteins. These proteins inhibit the function of pro-apoptotic 
proteins by the protein-protein interaction and prevent MOMP. The third group that 
consists of BAD, BID, BIM, PUMA, Noxa, etc. is called as BH3-only proteins. These 
proteins only share homology with the BH3 domain and they have the ability to bind and 
inhibit anti-apoptotic BCL-2 proteins. Some BH3-only proteins such as BIM and BID 
also have the ability to directly activate BAX and BAK proteins to promote apoptosis. 
Overall, BH3 only proteins promote MOMP and apoptosis.  
BAK (BCL-2 homologous antagonist killer) and BAX (BCL-2 associated X 
protein) have unique mechanisms to induce apoptosis. Without apoptotic stimuli, BAX is 
normally soluble in cytosol and BAK is inactivated by the interaction with MCL-1 or 
BCL-XL at the outer membrane of the mitochondria. The BH groove of the anti-apoptotic 
BCL-2 proteins prevents MOMP and apoptosis by binding to the BH3 domain of BAK or 
BAX to interfere the oligomerization. The BH grooves exist in all of the anti-apoptotic 
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BCL-2 proteins, but they need to be present in a hydrophobic environment such as the 
outer mitochondrial membrane. As apoptosis is induced, BAX is translocated to the 
mitochondria. On the other hand, BAK is freed from BAK-MCL-1 or BAK-BCL-XL 
complex. Conformational changes of BAK or BAX expose the BH3 domain to open their 
grooves, bind to a BH3 domain of either BAX or BAK, and form a dimer. Then BAX 
and/or BAK oligomerize and integrate into the outer mitochondrial membrane to form 
channels, which allow cytochrome c to release from the mitochondria followed by 
caspase activation and apoptosis.  
There are total of 11 BH3-only proteins identified in human and they have 
abilities to bind to the BH grooves of the anti-apoptotic BCL-2 proteins, but there is 
specificity for the interaction between BH3-only proteins and anti-apoptotic members. 
For example, BIM and BID are capable of interacting with all anti-apoptotic proteins. 
Noxa has a strong affinity to interact with MCL-1, however it has much less capability to 
bind to other anti-apoptotic proteins such as BCL-XL and BCL-2. In contrast, BAD and 
BMF have affinities only to BCL-XL and BCL-2, but not MCL-1. BID and BIM have 
another mechanism of binding to not only the anti-apoptotic proteins, but also BAX and 
BAK to trigger the oligomerization, which causes MOMP and initiates apoptosis.  
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Figure 4: List of the BCL-2 family of proteins. All BCL-2 family of proteins contains 
short BH (BCL-2 homology) domains [32]. 
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1.6 MCL-1 and Noxa 
MCL-1 (myeloid cell leukemia 1) was originally found in 1993 in the 
differentiating myeloid leukemia cell line [20]. It is composed of 350 amino acids in 
human and plays a critical role in regulating cell death and survival in both normal and 
cancer cells. The effect of MCL-1 is to prevent cell death by sequestering pro-apoptotic 
family members such as BAK or the BH3-only proteins (Noxa, BID, and BIM). Studies 
have shown that deletion of Mcl-1 in mice causes embryonic lethal phenotype, 
representing the significance of MCL-1 in early development [21]. The activity of MCL-1 
is regulated by its high turnover rate, which is mediated by phosphorylation, 
ubiquitination, and degradation. A region called PEST in MCL-1 governs MCL-1’s 
stability [35]. The PEST domain of MCL-1 contains multiple phosphorylation sites for 
protein kinases such as ERK, JNK, GSK3, CDK1 and CDK2. For example, GSK3 
(Glycogen synthase kinase 3) is a kinase that is activated by decrease in activation of 
AKT. When GSK3 is activated, MCL-1 is phosphorylated and ultimately is degraded. 
However, ERK-mediated phosphorylation of MCL-1 stabilizes the MCL-1 protein. It has 
been demonstrated that MCL-1 ubiquitin ligase E3 (MULE) and beta transducing-
containing protein (β-TrCP) are both E3-ubiquitin ligases that regulate MCL-1 stability. 
Other mechanisms that control the levels of MCL-1 are caspases and Granzyme B that 
cleave distinct sites within the N-terminus of MCL-1 during the progression of apoptosis. 
Cleaved MCL-1 reduces its ability to halt apoptosis stimulation. 
 Noxa is a pro-apoptotic BH3-only molecule that was originally identified as p53 
target gene [24]. The tumor suppressor p53 induces apoptosis in cells that are jeopardized 
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by cellular stresses. It has been shown that decreasing endogenous Noxa expression 
levels suppresses p53-dependent apoptosis. Noxa is known to affect the function of 
MCL-1 by binding to its BH3 domain to BH3 domain of MCL-1. Noxa specifically binds 
to and recruits MCL-1 from cytosol to the mitochondria [34]. Translocation of MCL-1 
initiates its phosphorylation and subsequent ubiquitination, which triggers proteasome-
mediated degradation [22]. Different types of signals can induce Noxa expression and its 
transcription and protein expression can be activated by both p53-dependent and -
independent manner. For example, DNA damage by cisplatin triggers p53 to induce Noxa, 
whereas a mitogenic stimulation activates PKC (protein kinase C) and induces Noxa 
independent of p53 [23]. DNA damage by ultraviolet radiation is also known to stimulate 
Noxa in fibroblasts and skin keratinocytes, and the significance of Noxa has been 
demonstrated in Noxa knockout mice [31]. 
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Figure 5: Noxa sequesters MCL-1 to release BAK form the BAK-MCL-1 complex and 
BAK oligomerizes to induce cell death [Modified 29].  
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1.7 p53 
A tumor suppressor, p53 has many important functions of anti-cancer functions. 
This 53 kDa protein in human has the abilities to prevent abnormal cell proliferation that 
might turn into tumors. p53 can also be activated by many stresses such as ultraviolet, x-
rays, chemotherapeutic drugs, and DNA synthesis inhibitors. All of these stresses rapidly 
increase the level of p53 protein by phosphorylating p53 by kinases such as Chk1, Chk2, 
and ATM, which prevents p53 degradation [33]. High concentration of p53 stops cell 
growth by holding the cell cycle at G1/S (cell cycle arrest) and induces DNA repair 
proteins to fix the damage and to prevent replication of the damaged DNA. If it is 
irreparable, p53 degradation is continuously blocked by phosphorylation. This initiates 
p53 to act as a transcription factor to induce the expressions of several pro-apoptotic 
target genes such as Noxa, Puma, and BAX for the apoptosis induction [33]. If the DNA is 
repaired, signals that protect p53 degradation disappear and the cell cycle resumes as the 
cell enters into the S phase to replicate its DNA. When the cell is in a normal state, p53 is 
rapidly degraded by a protein called Mdm2 (in mouse cells) and MDM2 (in human cells) 
[33]. This protein binds to the N-terminus of p53 when the kinases (Chk1, Chk2, and ATM) 
are not stimulated. The p53-Mdm2 complex triggers polyubiquitylation and proteasome-
mediated destruction.  
In order for tumors to thrive, tumor related mutant p53 alleles often carry point 
mutations in the reading frames that create missense codons (amino acid substitutions). 
Mutated p53 produces either a non-functional or a gain-of-function protein, which allows 
the tumor to grow uncontrollably. 
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HYPOTHESIS 
 
Cisplatin exerts anticancer effects via multiple mechanisms, yet its most 
prominent mode of action involves the generation of DNA lesions followed by the 
activation of the DNA damage response and the induction of BCL-2 family-dependent 
mitochondrial apoptosis.  DNA damage activates a tumor suppressor p53 to induce 
apoptosis.  One of its functions is to induce the expression of several pro-apoptotic 
proteins such as Noxa, which binds to an anti-apoptotic BCL-2 family protein, MCL-1 to 
inactivate its pro-survival function and induce apoptosis.  We hypothesized that Noxa-
MCL-1 axis is a crucial determinant of the efficacy of DNA-damaging agents for 
HNSCC treatment. 
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SPECIFIC AIMS 
 
3.1 Determine how Noxa and MCL-1 regulate apoptosis induced by cisplatin in 
HNSCC cells.  
Toxicity levels of cisplatin to a panel of HNSCC cell lines will be measured. 
Lentivirus-mediated shRNA (knock-down of Noxa) will be introduced to examine the 
contribution of Noxa to cisplatin-induced cell death.  
 
3.2 Determine the mechanisms of Noxa-induced cell death in HNSCC cells. 
The cells will be also infected with lentivirus harboring Flag-tagged Noxa cDNA to 
overexpress Noxa and cell death will be determined. Immunoprecipitation will be 
performed with anti-Flag antibodies to examine the binding affinity between Noxa 
and MCL-1. 
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MATERIALS AND METHODS 
 
4.1 Cell lines and Cell Culture 
HN4, HN12, HN22, HN8, HN30, and HN31 head and neck squamous cell 
carcinoma (HNSCC) cells were provided by Dr. Andrew Yeudall (Virginia 
Commonwealth University, VA). All cell lines were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) (Life Technologies) with addition of 10% heat-inactivated fetal 
bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA) and 5% 100 µg/mL 
penicillin G/streptomycin (Invitrogen) at 37°C in a humidified, 5% CO2 incubator. 293T 
cells were purchased from the American Type Culture Collection (Manassas, VA). 
HN30/sh-Noxa and HN31/sh-Noxa cells were maintained with 2 µg/mL of puromycin 
(InvivoGen, San Diego, CA) for selection. HN30/pCDH-Noxa and HN31/pCDH-Noxa 
cells were maintained using G418 (Fisher Scientific, Waltham, MA) at 0.4 mg/mL 
concentration for selection.  
 
4.2 Plasmid Transfection and Lentivirus Infection 
The lentiviral short-hairpin RNA (shRNA) expressing constructs were purchased 
from Open Biosystems (Huntsville, AL) or Sigma-Aldrich (St. Louis, MO). Flag-tagged 
Noxa cDNA was cloned into pCDH-EF1-MCS-IRES-neo (System Biosciences, 
Mountain View, CA). The constructs were transfected into 293T packaging cells along 
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with the packaging plasmids (Addgene; Cambridge, MA) and the lentivirus-
containing supernatants were used to HNSCC cell lines. 
 
4.3 Chemicals and Antibodies 
Cisplatin (sc-200896) was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). Antibodies for BIM, BCL-XL (54H6), Cleaved PARP (Asp214), HRP-linked 
anti-mouse IgG, and HRP-linked anti-rabbit IgG were from Cell Signaling Technology 
(Beverly, MA); MCL-1 (ADI-AAP-240-F) from Enzo Life Sciences (Farmingdale, NY); 
Alpha-Tubulin (sc-8035), BAX (sc-493), and p53 (sc-126) from Santa Cruz 
Biotechnology (Santa Cruz, CA); BAK from Millipore (Darmstadt, Germany); Noxa 
(114C307.1) from Thermo Fisher Scientific (Waltham, MA). ECL 2 Western blotting 
substrate (80196) was purchased from Thermo Scientific (Rockford, IL). Cell 
proliferation reagent WST-1 was purchased from Roche Diagnostics (Mannheim, 
Germany). 
 
4.4 Western Blot and Immunoprecipitation Analysis 
To perform Western blots, whole HNSCC cell lysates were prepared with CHAPS 
lysis buffer [20 mM Tris (pH 7.4), 137 mM NaCl, 1 mM dithiothreitol (DTT), 1% 
CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate), 1:200 ratio of 
protease inhibitor cocktail (Sigma Aldrich), and 1:100 ratio of phosphatase inhibitor 
cocktails 2 and 3 (Sigma)][30]. Protein concentrations from the lysates were measured by 
spectrophotometric analysis with Bradford method (Bio-rad, Hercules, CA), and equal 
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amounts of samples were loaded into SDS-polyacrylamide gel. The gel was 
electrophoresed at 200 volts for approximately 40 minutes and the proteins were 
transferred onto a nitrocellulose membrane (Fischer Scientific, Pittsburgh, PA) with 100 
volt for one hour. The nitrocellulose membrane was then blocked with blotting solution 
[5% skim milk in PBST (1 x PBS with 0.1% Tween-20)] for 20 minutes, and specific 
primary antibodies were incubated with the membrane for overnight at 4°C. The 
incubated membrane was washed with PBST for at least five minutes for three times and 
then either HRP-linked anti-mouse IgG or anti-rabbit IgG antibodies were incubated with 
the membranes for one hour at room temperature. The membranes were washed three 
times with PBST for five minutes. The membrane was then developed using Pierce ECL-
2 Western Blotting Substrate (Thermo Fisher Scientific).  
To perform immunoprecipitation (IP), 500 µg of protein sample was prepared to 
match a total volume to be 500 µL. The samples were then incubated with 40 µL of Anti-
FLAG M2 Affinity Gel (Sigma-Aldrich) for two hours on a rotating table at 4°C. After 
the incubation, the beads were washed by centrifugation for 30 seconds at 6000 rpm. 
Supernatants were removed and 1 mL of CHAPS buffer was added and incubated again 
on the rotating table for 5 minutes at 4°C. This step was repeated three times. The beads 
were then re-suspended in 30 µL CHAPS buffer with 5x sample buffer. The samples 
were loaded to SDS-PAGE gels. 
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4.5 Cell Toxicity (WST-1) Assay 
Head and neck squamous cell carcinoma cells were seeded in triplicate in 
microtiter plates (96 wells) with concentration of 1x104 cells per well in 150 µL medium. 
The following day, cells were treated with different concentration of cisplatin and 48 
hours later, 4 µL of WST-1 reagent were added to the cells. WST-1 assay is based on 
tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-
benzene disulphonate). It is used to determine the cytotoxicity of cisplatin by measuring 
the absorbance of the samples with a microplate enzyme-linked immunosorbent assay 
(ELISA) reader (Promega Life Sciences).  
 
4.6 IC50  
  IC50 (half maximal inhibitory concentration) is a term that represents an amount 
of specific substance (inhibitor) needed to inhibit 50 percent of cell’s biological or 
biochemical mechanisms, i.e. an enzyme, receptors or microorganism. IC50 for cisplatin 
cytotoxicity was calculated for each HNSCC cell line by obtaining quantitative 
measurements from the microplate ELISA 450nm reader. The measurements were 
entered in Excel sheets to calculate the IC50.  
 
4.7 Quantitative RT-PCR 
 To check if cisplatin treatment is effecting the mRNA levels of Noxa and MCL-1 
in HN22 and HN8 cells, total RNA was extracted with the RNA Mini prep kit (Genesee 
Scientific, San Diego, CA). One-microgram of RNA was reverse-transcribed by High 
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Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA). Taqman 
Gene Expression Assay probe/primer (Applied Biosystems) of MCL-1 (Hs03043899) 
and Noxa (Hs00560402) were used to amplify the cDNAs with fluorescence 
thermocycler (Applied Biosystems; 7500HT Fast Real-time PCR system) and were 
analyzed based on the expression level of GAPDH (Applied Biosystems, 4352934E) with 
SDS2.2 software. 
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RESULTS 
 
5.1 HNSCC cell lines 
Following list of head and neck squamous cell carcinoma cell lines were used in this 
study and their primary origin and main characteristics are outlined in Table 1. 
 
Table 1. HNSCC Cell lines 
Patient Cell line Origin p53 status 
A 
HN4 Base of tongue Truncated 
HN12 Lymph node Truncated 
B 
HN22 Epiglottis Deleted 
HN8 Lymph node Deleted 
C 
HN30 Pharynx Wild-type 
HN31 Lymph node Wild-type 
 
All three cell lines from the lymph node are metastatic. HN4 and HN12 cell lines have a 
mutation at the splicing donor site of exon 7 [28], thus produce a truncated form of p53, 
which is non-functional. The p53 genes are deleted in HN22 and HN8 cells, whereas 
HN30 and HN31 cells possess wild-type p53 gene [28]
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5.2 The expression of the BCL-2 family proteins and p53 in HNSCC cell lines 
We analyzed the endogenous expression levels of various BCL-2 family proteins 
and p53 (Figure 1a and 1b). Protein expression levels were determined by immunoblot 
analyses and tubulin or GAPDH (housekeeping proteins in cells) were employed as a 
control to demonstrate equal loading.  
The expression levels of BAK, BAX, and MCL-1 were relatively similar. BIM 
expression level in HN30 was very low compared to other cell lines, whereas HN31 had 
high Noxa expression level. The p53 levels in all cell lines correspond to the gene status 
of p53. In Figure 6b we observed a slight protein expression of ~40 kDa in HN4 and 
HN12 cell lines, no expression in HN22 and HN8 cell lines, and high expression of p53 
in HN30 and HN31. The faint bands represent the truncated, non-functional p53 in HN4 
and HN12 cells. The p53 gene was deleted in HN22 and HN8 cells, thus there was no 
expression. Wild-type p53 was expressed in HN30 and HN31, however, HN31 expressed 
significantly higher amount of p53 compared to HN30.  
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Figure 6: Expression levels of the BCL-2 family of proteins and p53. (a) Equal amounts 
of total lysates of HNSCC cells were subjected to immunoblot analyses using the 
indicated antibodies. (b) Total cell lysates were subjected to immunoblot analysis using 
anti-p53 antibodies. HN30 and HN31: wild-type p53; HN4 and HN12: truncated/non-
functional p53; HN22 and HN8: p53 was deleted. 
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5.3 Cisplatin sensitivity in HNSCC cell lines, IC50  
 IC50 of all cell lines with cisplatin treatment was determined with WST-1 assay. 
When the cells are metabolically active, WST-1 (tetrazolium) salt is turned into formazan 
dye, which can be quantified by a spectrophotometer at 450 nm (Figure 7).  
We found that IC50 values relatively correlated with p53 status in the cell lines. 
p53-truncated HN4 and HN12 had the highest IC50 of 75 µM and 63 µM, respectively 
and p53-deleted HN22 and HN8 cell lines both had IC50 of 50 µM . The p53-wild-type 
cell lines, HN30 and HN31 were the most sensitive cells to cisplatin. Twenty µM of 
cisplatin was required to kill half of HN30 and HN31 cell lines (Table 2 and Figure 8). 
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Figure 7: Cleavage of the tetrazolium salt WST-1 to formazan. (EC = electron coupling 
reagent, RS = mitochondrial succinate-tetrazolium-reductase system) 
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Table	  2.	  IC50	  values	  in	  HNSCC	  cell	  lines	  
HNSCC	  cell	  lines	   Cisplatin	  sensitivity,	  IC50	  (µM)	  
HN4	   75	  
HN12	   63	  
HN22	   50	  
HN8	   50	  
HN30	   21	  
HN31	   20	  
 
 
 
 
a 
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Figure 8: Cell viability determined by WST-1 assays. HNSCC cell lines were treated 
with various concentrations of cisplatin for 48 hours. (a) HN4 (b) HN12 (c) HN22 (d) 
HN8 (e) HN30 and (f) HN31 
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5.4 The contribution of Noxa to cisplatin-induced cell death 
To examine if cisplatin induces Noxa to cause cell death, we introduced short-
hairpin RNA (shRNA) for Noxa to knock-down Noxa expression. As control, we 
introduced non-targeting shRNA. Both sh-control and sh-Noxa expressing HNSCC cells 
were seeded in a 6-well plates and 20 µM of cisplatin was added to each well. Cells were 
harvested in 6 different time points, which revealed different expression levels of 
cleaved-PARP, MCL-1, and Noxa. Cleaved-PARP is one of the proteins cleaved by 
caspase-3 when apoptosis is occurred, therefore it was used to represent the induction of 
apoptosis. Figure 9a and 9b show clear reduction of cleaved-PARP levels with decreased 
Noxa expression. This decrease of cleaved-PARP expression suggests that Noxa is 
contributing to apoptosis by cisplatin in both HN30 and HN31 cells. The results also 
suggest the existence of Noxa-independent mechanisms to stimulate apoptosis.  
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Figure 9: The induction of Noxa is required for cisplatin-induced apoptosis in HNSCC 
cells. (a) HN30 and (b) HN31 cells were infected with lentivirus-encoding shRNA for 
non-targeting control or Noxa. Cells were then treated with cisplatin (20 µM) for the 
indicated times and equal amounts of total extracts were loaded to immunoblot analysis 
with indicated antibodies. 
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5.5 The contribution of p53 to cisplatin-induced cell death through Noxa-independent 
pathway 
 p53 is activated by DNA damaging agents such as cisplatin. Noxa is known as a 
p53 target gene. Thus, to examine whether Noxa-dependent apoptosis induced by 
cisplatin observed in Figure 9 is also p53-dependent, we introduced shRNA for p53 in 
HN30 cells to knock-down p53 expression. Both sh-control and sh-p53 expressing HN30 
cells were seeded in a 6-well plates and cells were treated with 20 µM of cisplatin. The 
level of cleaved-PARP was decreased in HN30 sh-p53 cells, whereas the induced level of 
Noxa was not much changed (Figure 10). This result suggests that cisplatin induces p53-
dependent/Noxa-independent pathway to stimulate apoptosis and that Noxa can be 
induced independent of p53.  
 
 
Figure 10: p53 contributes to cisplatin-induced apoptosis, but not to Noxa induction. 
Cells were infected with lentivirus-encoding shRNA for non-targeting control or p53. 
Cells were then treated with cisplatin (20 µM) for the indicated times and equal amounts 
of total extracts were loaded to immunoblot analysis with indicated antibodies. 
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5.6 Noxa induction with cisplatin in p53 null cells 
 In order to examine the contribution of Noxa in cisplatin-induced apoptosis in 
p53-independent manner, we introduced shRNA for Noxa in p53-null HN22 and HN8 
cells to knock-down Noxa expression. With IC50 results from WST-1 assay (Figure 8), 50 
µM of cisplatin was used to treat HN22 and HN8 cell lines expressing sh-control and sh-
noxa (Figure 11). Noxa is known to be the target gene of p53 [24], however, the 
immunoblot results in Figure 11a clearly showed the induction of Noxa with cisplatin 
treatment in both HN22 and HN8 p53-deleted cell lines. Figure 11b is showing mRNA 
levels of Noxa in HN22 and HN8 cells after cisplatin treatment. This data shows that 
cisplatin treatment induces Noxa by regulating transcription to increase the protein level. 
Down-regulation of Noxa reduced cisplatin-induced PARP-cleavage in HN22 cells 
(Figure 11c). These results suggest that Noxa can be induced by cisplatin with p53-
independent pathways and consequently stimulates apoptosis.  
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Figure 11: Noxa induction with cisplatin in p53-deleted cell lines. (a) HN22 and HN8 
cells were treated with 50 µM of cisplatin for the indicated times. (b) Cisplatin-treated 
HN22 and HN8 cells were harvested at the indicated times and mRNA levels of Noxa 
were measured by qRT-PCR. (c) HN22 and HN8 Cells were infected with lentivirus-
encoding shRNA for non-targeting control or Noxa. Cells were then treated with cisplatin 
(50 µM) for the indicated times and equal amounts of total extracts were loaded to 
immunoblot analysis with indicated antibodies.  
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Figure 12: Schematics of p53-dependent/ Noxa dependent and p53-independent/ Noxa 
dependent pathways. 
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5.7 Overexpression of Noxa in HNSCC cells induces cell death 
 Noxa is known to sequester MCL-1 to be degraded, allowing the effector protein 
BAK to be released and resulting in cell death. Thus, we wanted to investigate if up-
regulation of Noxa in HNSCC cells can induce apoptosis. We introduced Noxa cDNA 
using lentivirus-mediated transfection and a vector alone as control. The interaction of 
Noxa and MCL-1 was confirmed by immunoprecipitation followed by immunoblot 
analyses (Figure 13). We observed the increase of cleaved-PARP levels in all cell lines 
tested (Figure 14), suggesting that Noxa overexpression is sufficient to induce apoptosis 
in HNSCC cells regardless of the p53 gene status. However, the amount of MCL-1 
seemed to be differently by Noxa overexpression depending on the p53 status. HN4 and 
HN12 with truncated p53 had relatively similar amount of MCL-1 expression with or 
without Noxa overexpression. In contrast, p53-null HN22 and HN8 increased MCL-1 
expression. These results suggest that a clear induction of cleaved-PARP with Noxa 
overexpression can be detected even though MCL-1 is not degraded by Noxa expression.  
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Figure 13: Noxa and MCL-1 interaction in HN22 and HN8 cells. Overexpression of Flag 
tagged-Noxa shows strong interaction with MCL-1 in both cell lines. 
Immunoprecipitation was done with the agarose beads conjugated with anti-Flag 
antibodies to capture Flag-Noxa. Total lysate shows MCL-1 and Noxa expression to 
compare with the IP. GAPDH is used as the loading control for the total lysate and 
expression level of the heavy chain from the agarose beads are used as the loading 
control for IP. 
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Figure 14: Apoptosis induced by Noxa overexpression in HN4, HN12, HN22, HN8, 
HN30, and HN31. HNSCC cells were infected with lentivirus-encoding Flag-tagged 
Noxa cDNA or vector alone as control for 24 hour. Equal amounts of total extracts were 
added to immunoblot analysis with indicated antibodies. The loading control for HN4 
and HN12 were done with GAPDH, whereas HN22, HN8, HN30, and HN31 were done 
with alpha-tubulin. [C = control, wt = wild-type (overexpression) Noxa]
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DISCUSSION AND FUTURE DIRECTIONS 
 
6.1 The sensitivity of cisplatin is relatively correlated with the status of p53 in HNSCC 
cell lines 
 When DNA is damaged by cisplatin, p53 is induced to prevent DNA replication 
or to stimulate apoptosis when DNA cannot be repaired. The IC50 results demonstrated 
that cell lines with wild-type p53 (HN30 and HN31) had higher sensitivity to cisplatin 
compared to cell lines with p53 deletion or non-functional p53 (Figure 6b and Table 2). 
From these results we can speculate that cisplatin largely induces p53-dependent pathway 
to stimulate cell death, however with increased cisplatin concentration, p53-deleted cells 
are able to induce cell death as well. This might suggest the existence of a p53-
independent pathway(s) (Figure 12).  
 
6.2 Knock-down of Noxa decreased cleaved-PARP expression with cisplatin treatment 
 A BH3-only protein, Noxa is known as a target gene for p53 [24]. We observed 
that there was decrease in cleaved-PARP expression and stabilization of MCL-1 in HN30 
sh-Noxa, indicating that cisplatin-induced Noxa expression is required to stimulate 
apoptosis. Unlike HN30 sh-Noxa (Figure 9a), HN31 sh-Noxa (Figure 9b) still showed the 
reduction of MCL-1 expression in 16 and 24 hours after the treatment. Since endogenous 
Noxa expression in HN31 was much greater than HN30 (Figure 6a), the efficiency of 
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Noxa knock-down was not enough to decrease its expression. Noxa expression in 2, 4, 
and 8 hour period in HN31 sh-Noxa (Figure 9b) is clearly visible, therefore, this residual 
Noxa is likely to bind to MCL-1 and induce degradation. With overall results, we 
speculate that cisplatin can induce Noxa without p53, which could take longer time to 
induce cell death.  
 
6.3 Knock-down of p53 decreased cleaved-PARP expressions with cisplatin treatment 
 To further investigate the pathways for the induction of cell death by cisplatin, we 
knocked-down p53 to examine the effects of cleaved-PARP, MCL-1, and Noxa. The 
result showed clear induction of Noxa expression in both HN30 sh-control and sh-p53 
(Figure 10), but decrease in cleaved-PARP expression. Decrease in cleaved-PARP 
expression suggests that cisplatin induces a p53-dependent/Noxa-independent 
pathway(s). This result also suggests that Noxa can be induced not only by p53, but also 
by other mechanisms. However, we cannot conclude just by this result that p53-
dependent pathway is the main pathway for cisplatin-induced cell death.  
 
6.4 Noxa induction with cisplatin treatment in p53-deleted HNSCC cell lines  
 To analyze if Noxa expression can be seen in p53-deleted HN22 and HN8 cells by 
cisplatin, Western blots were performed with parental cells and with Noxa knock-down 
cells. The results (Figure 11a) clearly show the induction of Noxa in both HN22 and HN8 
parental cells. This data confirms that Noxa can be induced by a p53-independent 
pathway(s). Figure 11b suggests that because the Noxa mRNA levels are increasing, its 
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induction is regulated by transcription, not by post-transcription protein stabilization. 
This data also supports that Noxa can be induced without p53.  
Compared to p53 wild-type cells, these p53-deleted cells have more stable MCL-1 
expressions even with increased Noxa expression (Figure 11 and 14), suggesting that 
there might be a p53 target gene for a specific E3-ligase to ubiquitinate MCL-1. p53 
could also transcribe a target gene required for the MCL-1 localization at the outer 
membrane of mitochondria, which could enhance the stabilization of MCL-1. 
 
 6.5 Noxa overexpression can induce cell death regardless of p53 status  
 If exogenous Noxa expression can induce cell death, the status of p53 would not 
be prominent. Thus, we infected with lentivirus-encoding Flag-tagged Noxa cDNA to the 
HNSCC cell lines. Western blot results showed the increase of cleaved-PARP in all cell 
lines tested (Figure 14), suggesting that Noxa overexpression can induce apoptosis 
without consideration of p53 status. Because Noxa is downstream of p53, these results 
suggest that overexpression of Noxa is capable of inducing p53-independent/Noxa-
dependent pathway to increase apoptosis. This finding could be applicable as a potential 
therapeutic strategy to treat head and neck cancer.  
 
6.6 Future directions 
 More investigations should be conducted to elucidate the activation of p53-
independent/Noxa-dependent cell death and figure out what could be inducing the 
expression of Noxa. MCL-1 stabilization in p53-deleted cells should also be thoroughly 
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investigated. Findings of other mechanisms that might inhibit MCL-1 ubiquitination or 
phosphorylation in p53 deleted cells could help to unravel more on how Noxa/MCL-1 
proteins interactions are regulated.  
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